===
EQS-News: Evotec SE / Key word(s): Miscellaneous
Bayer and Evotec collaborate to advance precision cardiology
2024-04-30 / 08:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
. BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES
. STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF
NOVEL TARGETS
. JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION CARDIOLOGY

Berlin and Hamburg, Germany, 30 April 2024:
Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their
strategic collaboration to developing innovative precision treatments for cardiovascular diseases (CVDs).
The collaboration aims to identify and validate novel targets, with the goal of building a portfolio of precision
cardiology therapeutics by leveraging Evotec's disease modelling capabilities using human induced pluripotent stem
cells (iPSCs). iPSCs provide unique opportunities to identify new disease mechanisms and pathways for novel treatments.
Under the terms of the agreement, both companies will contribute drug targets and a comprehensive set of high-quality
technology platforms for the development of innovative treatment options.
"This development takes our long-standing collaboration with Evotec to a new level, and has the added benefit of
lessons learned from working together the past 12 years," said Juergen Eckhardt, M.D., Head of Business Development &
Licensing at Bayer's Pharmaceuticals Division. "We remain committed to develop innovative therapies for patients in
need and to tackle the high burden of cardiovascular disease."
"Cardiovascular diseases are the leading cause of death globally," said Dr Christian Rommel, Head of Research and
Development at Bayer's Pharmaceuticals Division. "The refocused collaboration will leverage Evotec's industrialised
iPSC-based disease modelling platform and Bayer's leadership in cardiology to advance a portfolio of innovative
therapies for cardiovascular diseases with high unmet medical need. This complements our focus on disease areas where
we can truly improve the standard of care by delivering superior therapeutic solutions to patients in need."
"In order to move the treatment paradigm beyond disease management, it is important to advance our understanding of the
disease-relevant molecular mechanisms underlying cardiovascular diseases," said Dr Cord Dohrmann, Chief Scientific
Officer of Evotec. "Our approach is based on highly validated disease models to identify novel targets and profile drug
candidates more comprehensively for their efficacy and safety. Intervening with these disease-associated mechanisms
more comprehensively will enable the development of more effective, disease modifying therapies with higher relevance
for CVD to respond to the substantial unmet need associated with cardiovascular diseases."
Bayer and Evotec will share responsibilities during the pre-clinical development of potential clinical candidates.
Bayer will be responsible for any subsequent clinical development and commercialisation.
No financial terms of the collaboration were disclosed.
ABOUT BAYER
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line
with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people
and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global
population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses.
At the same time, the Group aims to increase its earning power and create value through innovation and growth. The
Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around
100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros.
For more information, go to www.bayer.com.
Bayer Media Contact:
Lisa Hennig, phone +49 172 8693420
Email: lisa.hennig@bayer.com
ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop
highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a
unique combination of innovative technologies, data and science for the discovery, development, and production of
first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships
and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other
healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas,
including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise,
Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a
portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec
operates globally with more than 5,000 highly qualified people. The Company's 17 sites offer highly synergistic
technologies and services and operate as complementary clusters of excellence. For additional information please go to
www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and
listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may,"
"might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are
intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for
revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information
available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made.
No assurance can be given that such expectations will prove to have been correct. These statements involve known and
unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant
uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any
obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or
circumstances on which any statement is based.
Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications, Gabriele.Hansen@evotec.com
Hinnerk Rohwedder, Director of Global Corporate Communications, Hinnerk.Rohwedder@evotec.com
IR Contact Evotec SE:
Volker Braun, EVP Head of Global Investor Relations & ESG, Volker.Braun@evotec.com
2024-04-30 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      Evotec SE 

Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany

Phone:        +49 (0)40 560 81-0 
Fax:          +49 (0)40 560 81-222 
E-mail:       info@evotec.com 
Internet:     www.evotec.com 
ISIN:         DE0005664809 
WKN:          566480 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, 

Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 1892043

End of News EQS News Service
===
1892043 2024-04-30 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1892043&application_name=news

END) Dow Jones Newswires

April 30, 2024 02:30 ET (06:30 GMT)